Vasen H F A, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes F J, Hodgson S, Järvinen H, Mecklin J-P, Møller P, Myrhøi T, Nagengast F M, Parc Y, Phillips R, Clark S K, de Leon M Ponz, Renkonen-Sinisalo L, Sampson J R, Stormorken A, Tejpar S, Thomas H J W, Wijnen J
Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.
Gut. 2008 May;57(5):704-13. doi: 10.1136/gut.2007.136127. Epub 2008 Jan 14.
Familial adenomatous polyposis (FAP) is a well-described inherited syndrome, which is responsible for <1% of all colorectal cancer (CRC) cases. The syndrome is characterised by the development of hundreds to thousands of adenomas in the colorectum. Almost all patients will develop CRC if they are not identified and treated at an early stage. The syndrome is inherited as an autosomal dominant trait and caused by mutations in the APC gene. Recently, a second gene has been identified that also gives rise to colonic adenomatous polyposis, although the phenotype is less severe than typical FAP. The gene is the MUTYH gene and the inheritance is autosomal recessive. In April 2006 and February 2007, a workshop was organised in Mallorca by European experts on hereditary gastrointestinal cancer aiming to establish guidelines for the clinical management of FAP and to initiate collaborative studies. Thirty-one experts from nine European countries participated in these workshops. Prior to the meeting, various participants examined the most important management issues according to the latest publications. A systematic literature search using Pubmed and reference lists of retrieved articles, and manual searches of relevant articles, was performed. During the workshop, all recommendations were discussed in detail. Because most of the studies that form the basis for the recommendations were descriptive and/or retrospective in nature, many of them were based on expert opinion. The guidelines described herein may be helpful in the appropriate management of FAP families. In order to improve the care of these families further, prospective controlled studies should be undertaken.
家族性腺瘤性息肉病(FAP)是一种已被充分描述的遗传性综合征,在所有结直肠癌(CRC)病例中占比不到1%。该综合征的特征是在结肠直肠内形成数百至数千个腺瘤。如果几乎所有患者在早期未被识别和治疗,都会发展为结直肠癌。该综合征以常染色体显性性状遗传,由APC基因突变引起。最近,已鉴定出另一个基因,它也会导致结肠腺瘤性息肉病,尽管其表型不如典型的FAP严重。该基因是MUTYH基因,其遗传方式为常染色体隐性遗传。2006年4月和2007年2月,欧洲遗传性胃肠癌专家在马略卡岛组织了一次研讨会,旨在制定FAP临床管理指南并启动合作研究。来自9个欧洲国家的31位专家参加了这些研讨会。在会议之前,各位参与者根据最新出版物研究了最重要的管理问题。使用Pubmed及检索文章的参考文献列表进行了系统的文献检索,并手动检索了相关文章。在研讨会上,对所有建议进行了详细讨论。由于构成这些建议基础的大多数研究本质上是描述性的和/或回顾性的,其中许多基于专家意见。本文所述的指南可能有助于对FAP家族进行适当管理。为了进一步改善对这些家族的护理,应开展前瞻性对照研究。